Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for schizophrenia symptoms
NCT06838104Active, not recruiting
- Sponsor
- Lahore General Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in schizophrenia comparing Melatonin with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale Total Score at 8 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
melatonin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06838104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838104.